JPS648603B2 - - Google Patents
Info
- Publication number
- JPS648603B2 JPS648603B2 JP5263981A JP5263981A JPS648603B2 JP S648603 B2 JPS648603 B2 JP S648603B2 JP 5263981 A JP5263981 A JP 5263981A JP 5263981 A JP5263981 A JP 5263981A JP S648603 B2 JPS648603 B2 JP S648603B2
- Authority
- JP
- Japan
- Prior art keywords
- present
- adhesions
- sodium alginate
- drug
- abdominal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229940079593 drug Drugs 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 14
- 235000010413 sodium alginate Nutrition 0.000 claims description 14
- 229940005550 sodium alginate Drugs 0.000 claims description 14
- 239000000661 sodium alginate Substances 0.000 claims description 14
- 238000007912 intraperitoneal administration Methods 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 239000000644 isotonic solution Substances 0.000 claims description 3
- 239000002075 main ingredient Substances 0.000 claims description 2
- 238000012360 testing method Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 9
- 230000003187 abdominal effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000002350 laparotomy Methods 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 206010000050 Abdominal adhesions Diseases 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000002874 hemostatic agent Substances 0.000 description 3
- 208000008384 ileus Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 206010034650 Peritoneal adhesions Diseases 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- IAJILQKETJEXLJ-SQOUGZDYSA-N L-guluronic acid Chemical compound O=C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-SQOUGZDYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010058046 Post procedural complication Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5263981A JPS57167919A (en) | 1981-04-07 | 1981-04-07 | Preventing agent for intraperitoneal adhesion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5263981A JPS57167919A (en) | 1981-04-07 | 1981-04-07 | Preventing agent for intraperitoneal adhesion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57167919A JPS57167919A (en) | 1982-10-16 |
| JPS648603B2 true JPS648603B2 (enrdf_load_stackoverflow) | 1989-02-14 |
Family
ID=12920397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5263981A Granted JPS57167919A (en) | 1981-04-07 | 1981-04-07 | Preventing agent for intraperitoneal adhesion |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS57167919A (enrdf_load_stackoverflow) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143724A (en) * | 1990-07-09 | 1992-09-01 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
| US5266326A (en) * | 1992-06-30 | 1993-11-30 | Pfizer Hospital Products Group, Inc. | In situ modification of alginate |
| KR20010107067A (ko) * | 2000-05-25 | 2001-12-07 | 김정식 | 유착방지제 |
| JP2003024431A (ja) * | 2001-07-18 | 2003-01-28 | Kuraray Co Ltd | 癒着防止材およびその製造方法 |
| CA2527429A1 (en) * | 2003-05-30 | 2004-12-09 | Arc Pharmaceuticals, Inc. | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents |
| JP4752817B2 (ja) * | 2007-07-04 | 2011-08-17 | 日本精工株式会社 | 軸受装置および軸受装置の組立方法 |
| WO2012085609A1 (en) | 2010-12-20 | 2012-06-28 | Dept. Of Pathobiology | Treatment of osteoarthritis by continuous intra-articular injection of alginate gel |
| CN103505657B (zh) * | 2013-10-17 | 2015-05-06 | 常鲁 | 一种治疗腹腔手术后肠功能紊乱的护脐贴及其制备方法 |
| CN106457750B (zh) | 2014-03-31 | 2020-09-08 | 东丽株式会社 | 多层片材和使用其得到的一体化片材以及其制造方法 |
-
1981
- 1981-04-07 JP JP5263981A patent/JPS57167919A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57167919A (en) | 1982-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DeCherney | Clinical problem of intraperitoneal postsurgical adhesion formation following general urgery and the use of adhesion prevention barriers | |
| Cohen et al. | Prevention of postoperative abdominal adhesions by a novel, glycerol/sodium hyaluronate/carboxymethylcellulose-based bioresorbable membrane: a prospective, randomized, evaluator-blinded multicenter study | |
| Halebian et al. | Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids | |
| Soper et al. | Laparoscopic cholecystectomy during pregnancy | |
| Sjövall et al. | Blunt abdominal trauma in children: risks of nonoperative treatment | |
| Pitt et al. | Management of hepatic echinococcosis in Southern California | |
| Symbas et al. | Spontaneous rupture of the esophagus | |
| Schiffrin et al. | Some factors concerned in the production of experimental ulceration of the Gl tract in cats | |
| JPS648603B2 (enrdf_load_stackoverflow) | ||
| Hanson et al. | Clinical evaluation of cimetidine, sucralfate, and misoprostol for prevention of gastrointestinal tract bleeding in dogs undergoing spinal surgery | |
| US20150010636A1 (en) | Apparatus and Method for Reducing the Occurrence of Post-Surgical Adhesions | |
| US8075908B2 (en) | Apparatus and method for reducing the occurrence of post-surgical adhesions | |
| Murphy et al. | Use of a high-molecular-weight carboxymethylcellulose in a tissue protective solution for prevention of postoperative abdominal adhesions in ponies | |
| Buckenmaier III et al. | Effect of the Antiadhesive Treatments, Carboxymethylcellulose Combined with Recombinant Tissue Plasminogen Activator and Seprafilm™, on Bowel Anastomosis in the Rat | |
| US20040009917A1 (en) | Method for the reduction or prevention of post-surgical adhesion formation | |
| Basu | Perforation of the bowel in Henoch-Schönlein purpura | |
| Reijnen et al. | Hyaluronic acid‐based agents do not affect anastomotic strength in the rat colon, in either the presence or absence of bacterial peritonitis | |
| Cutler Jr | Urgent surgery in the aged | |
| EP0059221A1 (en) | Agent for alimentary canal | |
| Dixon et al. | Closure of colonic stoma: improved results with combined succinylsulfathiazole and sulfathiazole therapy | |
| WO2002030445A2 (en) | Fibrinogen plus a non-plasmin-acting fibrinolysis inhibitor for the reduction or prevention of adhesion formation | |
| HUT68560A (en) | The use of xantine derivatives for promotion of healing of operative lesions | |
| JP3545790B2 (ja) | 腹腔内の癒着防止剤 | |
| Poth | The practical application of intestinal antisepsis to surgery of the colon and rectum | |
| JP2002536323A (ja) | 膿瘍形成の予防 |